POLE and cancer: All cancers had a known pathogenic POLE mutation, as described by León‐Castillo et al18, including p.Pro286Arg (1), p.Val411Leu (4), p.Ser297Phe (2), p.Ser459Phe (1), p.Phe367Ser (2), p.Leu424Ile (1), and p.Met295Arg (1).